HC Wainwright Brokers Lower Earnings Estimates for DRTS

Alpha Tau Medical Ltd. (NASDAQ:DRTS) – Stock analysts at HC Wainwright reduced their Q2 2026 EPS estimates for Alpha Tau Medical in a research note issued on Wednesday, May 20th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of ($0.14) for the quarter, down from their previous forecast of ($0.13). HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Alpha Tau Medical’s current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for Alpha Tau Medical’s Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.67) EPS, Q2 2027 earnings at ($0.14) EPS, Q3 2027 earnings at ($0.14) EPS and FY2027 earnings at ($0.55) EPS.

A number of other research firms also recently issued reports on DRTS. Piper Sandler upped their price target on shares of Alpha Tau Medical from $5.00 to $8.00 and gave the company a “neutral” rating in a research note on Tuesday. Zacks Research upgraded Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 17th. Citigroup boosted their price objective on shares of Alpha Tau Medical from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, March 11th. LADENBURG THALM/SH SH increased their price target on Alpha Tau Medical from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Alpha Tau Medical in a report on Monday, April 20th. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Alpha Tau Medical presently has an average rating of “Hold” and an average target price of $11.50.

Alpha Tau Medical Price Performance

Shares of Alpha Tau Medical stock opened at $10.96 on Friday. The firm has a market cap of $964.59 million, a PE ratio of -16.36 and a beta of 1.11. Alpha Tau Medical has a 12 month low of $2.81 and a 12 month high of $11.62. The stock has a 50 day moving average of $7.96 and a 200 day moving average of $6.52. The company has a current ratio of 7.79, a quick ratio of 7.45 and a debt-to-equity ratio of 0.09.

Alpha Tau Medical (NASDAQ:DRTS) last issued its earnings results on Monday, May 18th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13).

Hedge Funds Weigh In On Alpha Tau Medical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Trifecta Capital Advisors LLC acquired a new stake in shares of Alpha Tau Medical during the fourth quarter worth about $48,000. Envestnet Asset Management Inc. purchased a new stake in shares of Alpha Tau Medical during the 3rd quarter worth about $62,000. Principal Financial Group Inc. acquired a new stake in Alpha Tau Medical in the first quarter valued at approximately $132,000. Bank of America Corp DE grew its stake in Alpha Tau Medical by 2,779.1% in the 3rd quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock valued at $101,000 after acquiring an additional 21,677 shares during the period. Finally, Wells Fargo & Company MN grew its position in shares of Alpha Tau Medical by 291.7% in the fourth quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock valued at $116,000 after purchasing an additional 17,500 shares during the period. Hedge funds and other institutional investors own 2.65% of the company’s stock.

Alpha Tau Medical News Roundup

Here are the key news stories impacting Alpha Tau Medical this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating on Alpha Tau Medical and maintained a $15 price objective, signaling continued confidence in the company’s longer-term growth outlook. Alpha Tau Medical (NASDAQ:DRTS) Receives “Buy” Rating from HC Wainwright
• Positive Sentiment: The firm’s target price suggests roughly 36.9% upside from the recent share price, which may be encouraging investors despite ongoing losses. Benzinga
• Neutral Sentiment: HC Wainwright also laid out multiple earnings estimates for 2026 and 2027, with losses of about $0.14 per share per quarter expected in the near term and FY2026 EPS of -$0.67, indicating the company is still not expected to be profitable soon.
• Negative Sentiment: The analyst trimmed several EPS forecasts, including Q2 2026, Q3 2026 and Q4 2026, and cut the FY2026 estimate to a larger loss than before, which could temper enthusiasm.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.